Columbia Labs Appoints George Elston As CFO

(RTTNews) - Columbia Laboratories, Inc. (CBRX), a provider of pharmaceutical development, clinical trial manufacturing, and advanced analytical and consulting services to the pharmaceutical industry, announced that it has appointed George Elston, 50, as Chief Financial Officer, effective October 1. He succeeds Jonathan Lloyd Jones, who is stepping down from the role to pursue other opportunities.

Elston is an experienced finance executive who has been the CFO of several pharmaceutical development and life science companies. He joins Columbia from KBI Biopharma, a biopharmaceutical contract development and manufacturing firm, where he served as Senior Vice President and CFO, and was responsible for all financial operations.

Elston is also a board member at Celldex Therapeutics, Inc. and chair of the audit committee, in addition to serving as a trustee for the Deutsche Bank DBX ETF Trust. Previously, Elston served as a senior executive at Optherion, Inc., a biopharmaceutical company developing biologic drugs for the treatment of ophthalmic and autoimmune diseases, and Elusys Therapeutics, a biopharmaceutical company developing antibody based therapies for life threatening infectious diseases.

In addition to these roles, Elston was the founder and managing partner at Chatham Street Partners, which provided strategic and CFO advisory services to the executive management and boards of life science companies.